| Code | CSB-RA896537MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is a research-grade biosimilar to INCAGN1876, targeting TNFRSF18 (tumor necrosis factor receptor superfamily member 18), also known as GITR (glucocorticoid-induced TNFR-related protein). TNFRSF18 is a co-stimulatory receptor predominantly expressed on regulatory T cells (Tregs) and activated effector T cells, playing a critical role in modulating immune responses. Upon engagement with its ligand GITRL, TNFRSF18 enhances T cell activation, proliferation, and effector function while potentially reducing Treg-mediated immunosuppression. This receptor has emerged as an important checkpoint molecule in cancer immunology, as its activation can shift the balance from immunosuppression to anti-tumor immunity in the tumor microenvironment.
INCAGN1876 is an investigational agonistic antibody designed to stimulate TNFRSF18 signaling to enhance anti-tumor immune responses, particularly in combination with other immunotherapeutic approaches. This biosimilar antibody serves as a valuable research tool for investigating TNFRSF18 biology, T cell co-stimulation mechanisms, immune checkpoint modulation, and potential immunotherapeutic strategies in oncology and autoimmune disease models.
There are currently no reviews for this product.